Shaun Fleming

Shaun Fleming

Auto-generated profile, based on publicly available information

Shaun Fleming

Malignant Haematology Transplantation & Cellular Therapy Services, Alfred Hospital, VIC, Australia

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications


1 August 2014 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
SFShaun Fleming
Shaun Fleming
SHSimon J. Harrison
Simon J. Harrison
PBPiers Blombery
Piers Blombery
TJTrish Joyce
Trish Joyce
KSKerrie Stokes
Kerrie Stokes
DRDavid Ritchie
David Ritchie

27 November 2025 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
CKChristina Kazzi
Christina Kazzi
SGSarah P. Griffith
Sarah P. Griffith
KKKatherine Y. Ko
Katherine Y. Ko
DPDaniel J. Pearce
Daniel J. Pearce
MWMiriam Wronski
Miriam Wronski
MMMastura Monif
Mastura Monif
Cognitive dysfunction is a common manifestation of immune effector cell-associated neurotoxicity syndrome (ICANS) following chimeric-antigen receptor (CAR) T-cell therapy. With CAR-T therapy indications rapidly expanding beyond traditional indications, it has become increasingly important to understand CAR-T therapy-related neurotoxicity and cognitive impairment to optimise treatment safety, and to improve monitoring and management. This study examined the Repeatable Battery of the Assessment of Neuropsychological Status (RBANS) as a tool for monitoring subacute cognitive recovery. In this prospective, single-centre cohort study, patients undergoing CAR T-cell therapy at The Alfred Hospital in Melbourne were evaluated with the RBANS at Day+1, Day+7, and a subacute outpatient visit (median 45 days post-infusion, IQR: 38 - 52). 238 RBANS administrations were conducted on eighty-seven patients (63% male, mean age of 66.2 years at infusion). Thirty (34%) patients developed ICANS. General linear mixed-effects models found significant time by ICANS group interactions. Post-hoc comparisons revealed that the ICANS group demonstrated significantly worse Attention, Language, and Total Index scores at Day+7, and significantly worse Total Index score at subacute review compared to the no ICANS group. Supplementary analyses also demonstrated that the higher grade (Grades 3 and 4) ICANS group performed worse than low-grade (Grades 1 and 2) and no ICANS groups. Patients who developed ICANS demonstrated deficits in attention and language. These cognitive deficits may persist for more than 45 days post-infusion in some patients. The RBANS shows potential as a valid measure of ICANS-related cognitive dysfunction, which can be used at the bedside and in clinic, as well as in research settings.